What Is Tesamorelin Approved For? Label Indications, Per the Research

The short answer

Tesamorelin is a prescription medicine, and its approved use is narrow. In the United States it carries a single labelled indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. A 2012 review in Annals of Pharmacotherapy described tesamorelin as a growth hormone-releasing factor analogue developed and approved for HIV-associated lipodystrophy, and summarised the efficacy and safety data that supported that indication (PMID 22298602). United States Food and Drug Administration records date the original approval of the brand product Egrifta to November 2010; regulatory listings, not individual studies, are the authoritative source for approval dates and label wording, and those documents are updated over time.

Every other context in which tesamorelin appears in the published literature — liver fat in metabolic dysfunction-associated steatotic liver disease, physical function in ageing adults with HIV, nerve repair, body composition in people without HIV, sports or aesthetic applications — sits outside that approved indication. Those contexts are described below in a separate section so they are never confused with the label. This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any medicine, including tesamorelin, is appropriate for a given person.

What the approved indication covers

The labelled population is specific: adults living with HIV who have developed lipodystrophy with excess visceral (intra-abdominal) fat. The endpoint behind that indication is anatomical — change in visceral adipose tissue measured by imaging — rather than a symptom score or a clinical event rate. A 2009 review in Expert Opinion on Investigational Drugs, written while the compound was still in late-stage development, characterised tesamorelin as a synthetic human growth hormone-releasing factor analogue that stimulated endogenous growth hormone secretion and was being evaluated for visceral adiposity in HIV (PMID 19243281).

Two points about the indication are frequently misread:

• It is an HIV-specific indication. The approval language is tied to HIV-associated lipodystrophy, not to abdominal obesity generally.
• It is a fat-distribution indication, not a weight-loss indication. The pivotal programme measured visceral adipose tissue, and reviews of that programme framed the benefit in those terms (PMID 22298602).

Why the HIV context matters biologically

The rationale for a growth hormone-releasing factor analogue in this population comes from endocrine changes described in HIV. A 2013 review in Reviews in Endocrine & Metabolic Disorders examined the pathophysiology of the GHRH–growth hormone–IGF-1 axis in HIV/AIDS and reported that alterations in this axis were associated with the body-composition changes, including visceral fat accumulation, seen in treated HIV (PMID 23657561). That review positioned agents acting at the GHRH receptor as a mechanistically targeted approach in that specific population, which is consistent with how the indication was ultimately written.

How the mechanism is described

Published reviews describe tesamorelin as acting upstream of growth hormone itself: rather than supplying exogenous growth hormone, it stimulates the pituitary through the GHRH receptor, with downstream effects on IGF-1 (PMID 19243281). A 2026 review of therapeutic peptides in aesthetic, metabolic and endocrine conditions placed tesamorelin among peptides with defined endocrine mechanisms and formal clinical evaluation, and distinguished such agents from peptides whose metabolic claims rest on preliminary data (PMID 42123471).

Trial evidence behind the label

The registrational evidence base was built in adults with HIV and excess visceral fat. The 2012 Annals of Pharmacotherapy review synthesised that programme and reported reductions in visceral adipose tissue with tesamorelin relative to placebo, alongside the safety signals monitored across those trials (PMID 22298602). The earlier 2009 review covered the same development programme at an earlier stage and summarised the pharmacology and the clinical questions the phase programme was designed to answer (PMID 19243281).

Because HIV treatment has changed substantially since those trials, later work re-examined the medicine in contemporary regimens. A 2024 study published in AIDS evaluated the efficacy and safety of tesamorelin in people with HIV receiving integrase strand transfer inhibitors, a drug class associated with weight gain, and the researchers reported findings on body composition and tolerability in that modern treatment setting (PMID 38905488). That work does not change the labelled indication; it addresses whether the original evidence generalises to people on current antiretroviral regimens.

Approved versus investigational: a side-by-side view

Investigational and off-label areas, clearly separated

None of the following are approved indications. They are research directions described in the published literature, and some are still at the protocol stage.

Liver fat and steatotic liver disease

A 2025 review in Current Opinion in HIV and AIDS examined metabolic dysfunction-associated steatotic liver disease in people with HIV and discussed therapeutic options and research directions in that population, a field in which growth hormone axis agents have been studied (PMID 40397552). More broadly, a 2021 review in Drug Design, Development and Therapy described the non-alcoholic steatohepatitis drug landscape as crowded and mechanistically diverse, reflecting how many candidate approaches have been pursued without a settled standard of care (PMID 34588764). Liver-fat reduction is not part of the tesamorelin label.

Physical function in people with HIV

A 2026 protocol published in BMJ Open described TRIUMPH, a clinical trial designed to test tesamorelin as an adjunct to exercise for improving physical function in people with HIV (PMID 42419889). A protocol publication sets out methods and endpoints; it does not report outcomes, and it does not establish effectiveness for that purpose.

Musculoskeletal and performance contexts

Two recent reviews addressed the gap between approved peptide indications and the way peptides are discussed in sport. A 2026 review in Sports Medicine examined the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, and the authors reported that evidence for performance and injury-recovery applications was substantially weaker than for the narrow indications these agents were approved to treat (PMID 41966639). A 2026 primer in The American Journal of Sports Medicine similarly reviewed injectable peptide therapy for orthopaedic and sports medicine clinicians and emphasised distinguishing regulatory status from marketing claims (PMID 41476424). Growth hormone and its secretagogues are also prohibited in competition under anti-doping rules, which is a separate regulatory layer from drug approval.

Nerve repair

A 2016 review in Expert Opinion on Therapeutic Targets discussed therapeutic augmentation of the growth hormone axis as a strategy to improve outcomes after peripheral nerve injury, framing it as a target of interest rather than an established therapy (PMID 27192539). This remains an investigational concept.

Tesamorelin Safety: What Studies Report

Safety data in the published literature come almost entirely from the HIV population in which the medicine was studied. The 2012 review summarised the tolerability profile observed across the development programme, including injection-site reactions and effects on glucose and IGF-1 that were monitored during treatment (PMID 22298602). The 2024 AIDS report assessed both efficacy and safety in people with HIV on integrase inhibitor regimens and the researchers reported tolerability outcomes alongside body-composition results (PMID 38905488). The 2026 Sports Medicine review noted that when peptides are used outside approved indications and outside clinical supervision, the safety data generated in regulated trials may not transfer to those settings (PMID 41966639).

Monitoring considerations, contraindications and interactions are set out in product labelling and are matters for a prescribing clinician, who can weigh them against an individual's history. No dosing information is provided on this page.

How to read a label indication

1. Indication defines the studied population. Approval reflects trials in adults with HIV-associated lipodystrophy; it says nothing about effects in other populations (PMID 22298602).
2. Approval is jurisdiction-specific. Availability and label wording differ between regulators, and national medicines agencies are the primary source for current status in each country.
3. Labels change. Formulations, supply status and label text are revised over time; the current regulatory listing supersedes any secondary summary, including this one.
4. Investigational is not approved. A published protocol, such as the TRIUMPH trial, describes a question under study rather than a demonstrated benefit (PMID 42419889).

Key takeaways

• Tesamorelin is a prescription medicine with one US label indication: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy (PMID 22298602).
• Its mechanism is described as GHRH-receptor stimulation of endogenous growth hormone, with downstream IGF-1 effects (PMID 19243281).
• The endocrine rationale is grounded in documented GHRH–GH–IGF-1 axis changes in HIV (PMID 23657561).
• Contemporary evidence has extended to people on integrase inhibitor regimens (PMID 38905488).
• Liver, physical-function, nerve and performance applications are investigational or off-label, and reviews have cautioned against treating them as established (PMID 41966639).

For a broader overview of the compound's pharmacology and evidence base, see the related hub page at /learn/tesamorelin/. Questions about whether tesamorelin is appropriate, available or advisable in any individual case belong with a licensed prescribing clinician.

References

• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (The Annals of Pharmacotherapy, 2012)
• Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009)
• Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024)
• Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS (Reviews in Endocrine & Metabolic Disorders, 2013)
• Metabolic dysfunction-associated steatotic liver disease in people with HIV (Current Opinion in HIV and AIDS, 2025)
• Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease (Drug Design, Development and Therapy, 2021)
• Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol (BMJ Open, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives (International Journal of Molecular Sciences, 2026)
• Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury (Expert Opinion on Therapeutic Targets, 2016)